Latest & greatest articles for dementia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dementia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dementia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dementia

101. Cohort study: People who face the bereavement of a partner with dementia have poorer mental health than those whose partners are dying from other diseases

Cohort study: People who face the bereavement of a partner with dementia have poorer mental health than those whose partners are dying from other diseases People who face the bereavement of a partner with dementia have poorer mental health than those whose partners are dying from other diseases | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how (...) we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here People who face the bereavement of a partner with dementia have poorer mental health than those

2018 Evidence-Based Nursing

102. Frontotemporal dementia

Frontotemporal dementia Frontotemporal dementia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Frontotemporal dementia Last reviewed: February 2019 Last updated: August 2018 Summary Manifests primarily as disruption in personality and social conduct, or as a primary language disorder. Almost 50% of all affected people display parkinsonism; a smaller subset may have motor neuron disease. Clinical diagnosis derives (...) primarily from examination and brain imaging. Diagnostic confirmation is based on pathological examination or identification of gene mutation. Treatment is supportive, combining medications with carer guidance, community services, and social work interventions. Definition Frontotemporal dementias (FTDs) are the second most frequent primary neurodegenerative brain diseases (after Alzheimer’s disease) in adults <65 years of age. The FTD spectrum comprises a heterogeneous group of conditions that appear

2018 BMJ Best Practice

103. Assessment of dementia

Assessment of dementia Assessment of dementia - Differential diagnosis of symptoms | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Assessment of dementia Last reviewed: February 2019 Last updated: September 2018 Summary Dementia is a syndrome characterised by an appreciable deterioration in cognition resulting in behavioural problems and impairment in the activities of daily living. Decline in cognition is extensive, often affecting multiple domains (...) of intellectual functioning. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., (DSM-5). Washington, DC: American Psychiatric Publishing; 2013. Cummings JL, Benson DF. Dementia: a clinical approach. 2nd ed. Boston: Butterworth-Heinemann; 1992. The prevalence of dementia is approximately 1% at the age of 60 years, and doubles every 5 years, to reach 30% to 50% by the age of 85 years. The majority of cases of dementia have degenerative and vascular causes. Thal LJ

2018 BMJ Best Practice

104. Vascular dementia

Vascular dementia Vascular dementia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Vascular dementia Last reviewed: February 2019 Last updated: August 2018 Summary Chronic progressive multifaceted impairment of cognitive function; a form of dementia. Loss of brain parenchyma is predominately from cerebrovascular causes such as infarction and small-vessel changes. The second most common cause of dementia in older (...) people. A large overlap exists with Alzheimer's dementia and many patients have a mixed form of dementia. Treatment is of limited benefit; early aggressive treatment of vascular risk factors is suggested. Definition Vascular dementia is a chronic progressive disease of the brain bringing about cognitive impairment. The executive functions of the brain such as planning are more prominently affected than memory. Motor and mood changes are often seen early. The underlying damage occurs to both grey

2018 BMJ Best Practice

105. Dementia with Lewy bodies

Dementia with Lewy bodies Dementia with Lewy bodies - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Dementia with Lewy bodies Last reviewed: February 2019 Last updated: August 2018 Summary A neurodegenerative disorder with parkinsonism, progressive cognitive decline, prominent executive dysfunction, and visuospatial impairment. Core clinical features include: recurrent visual hallucinations; cognitive fluctuations (...) )-type pathology. Meta-analyses support the use of cholinesterase inhibitors for the cognitive and the neurobehavioural symptoms. Memantine may be of some value in the treatment of dementia and behavioural symptoms. The use of antipsychotic medication must be minimised due to the increased sensitivity to these medicines' adverse effects, including increased mortality. Levodopa/carbidopa can be used for the motor symptoms, though adverse effects may be restrictive and response limited; clonazepam

2018 BMJ Best Practice

106. Alzheimer's dementia

Alzheimer's dementia Alzheimer's dementia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Alzheimer's dementia Last reviewed: February 2019 Last updated: September 2018 Summary Chronic, progressive neurodegenerative disorder characterised by a global, non-reversible impairment in cerebral functioning. Characterised by memory loss, loss of social and occupational functioning, diminished executive function, speech (...) support groups are beneficial to caregivers and should be considered, where available. Definition Alzheimer's disease (AD) is a chronic neurodegenerative disease with an insidious onset and progressive but slow decline. AD is the most common type of dementia. Grossman H, Bergmann C, Parker S. Dementia: a brief review. Mt Sinai J Med. 2006 Nov;73(7):985-92. http://www.ncbi.nlm.nih.gov/pubmed/17195884?tool=bestpractice.com Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population

2018 BMJ Best Practice

107. Specialist dementia care units

Specialist dementia care units Specialist dementia care units An Evidence Check rapid review brokered by the Sax Institute for the Commonwealth Department of Health. September 2017 An Evidence Check rapid review brokered by the Sax Institute for the Commonwealth Department of Health. September 2017. This report was prepared by: Malcolm Masso, Cathy Duncan, Pam Grootemaat, Lyn Phillipson, Peter Samsa, Dave Fildes and Rob Gordon. Australian Health Services Research Institute, University (...) www.saxinstitute.org.au knowledge.exchange@saxinstitute.org.au Phone: +61 2 91889500 Suggested Citation: Masso M, Duncan C, Grootematt P, Phillipson L, Samsa P, Fildes D, Gordon R. Specialist dementia care units: an Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the Commonwealth Department of Health, 2017. Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency

2018 Sax Institute Evidence Check

108. Dementia Friendly Design Features for Walking Paths: A Focus Practice Question

Dementia Friendly Design Features for Walking Paths: A Focus Practice Question Dementia Friendly Design Features for Walking Paths A Focused Practice Question Kim McAdam, Analyst, Research and Policy Sharon Williams, Supervisor Research, Policy and Planning Team Chronic Disease and Injury Prevention Region of Peel Public Health March 2017 i Table of Contents Key Messages 1 Issue & Context 2 Literature Review Question 4 Literature Search 4 Relevance Assessment 5 Results of the Search 6 Critical (...) Appraisal 6 Description of Included Studies 7 Synthesis of Findings 9 Relevance to Practice 15 References 15 Appendices 15 Appendix A: Search Strategy 16 Appendix B: Literature Search Flowchart 18 Appendix C: Data Extraction Tables 19 1 Key Messages 1. Design features of walking paths that can support older adults with dementia in safe physical activity, recreation and leisure, and social interaction include: continuous circulation loops with destination points and no dead ends, varying route lengths

2018 Peel Health Library

109. Randomised controlled trial: Self-management programme for people with dementia and their spouses demonstrates some benefits, but the model has limitations Full Text available with Trip Pro

Randomised controlled trial: Self-management programme for people with dementia and their spouses demonstrates some benefits, but the model has limitations Self-management programme for people with dementia and their spouses demonstrates some benefits, but the model has limitations | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Self-management programme for people with dementia and their spouses demonstrates some benefits

2018 Evidence-Based Nursing

110. Management of behavioural and psychological symptoms of dementia by an aroma-massage with acupressure treatment protocol: A randomised clinical trial (Abstract)

Management of behavioural and psychological symptoms of dementia by an aroma-massage with acupressure treatment protocol: A randomised clinical trial This study evaluates the clinical effectiveness of a multicomponent aroma-massage with an acupressure treatment protocol and compared it to cognitive training for the management of behavioural and psychological symptoms of dementia.Pharmacological interventions have been unsatisfactory in managing behavioural and psychological symptoms of dementia (...) ; thus, complementary and alternative medicine has been extensively researched to identify an adjunct safe and cost-effective intervention.This randomised clinical trial utilised a three-arm parallel group design. Cognitive training was used as a conventional intervention to manage behavioural and psychological symptoms of dementia, whereas exercise was considered "treatment as usual" in this study; both were used as comparisons with the experimental protocol. There were three treatment groups: Group

2018 EvidenceUpdates

111. Less dementia with oral anticoagulation in atrial fibrillation Full Text available with Trip Pro

Less dementia with oral anticoagulation in atrial fibrillation The association between atrial fibrillation (AF) and dementia is well documented, but it is not clear if oral anticoagulant treatment offers protection. The aim of the study is therefore to compare the incidence of new dementia in patients with AF with and without oral anticoagulants, and to explore if there is a difference between novel anticoagulants and warfarin in this respect.Retrospective registry study of all patients (...) with hospital diagnosis of AF and no previous diagnosis of dementia in Sweden between 2006 and 2014. Propensity score matching, falsification endpoints, and analyses according to intention to treat as well as on-treatment principles were used. The study included 444 106 patients and over 1.5 million years at risk. Patients on anticoagulant treatment at baseline was associated with 29% lower risk of dementia than patients without anticoagulant treatment [hazard ratio (HR) 0.71, 95% confidence intervals (95

2018 EvidenceUpdates

112. Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease

Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease '); } else { document.write(' '); } ACE | Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease Search > > Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease - Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease Published on 5 February 2018 (...) Guidance Recommendation The Ministry of Health's Drug Advisory Committee has recommended: Rivastigmine patch formulation (4.6mg/24h and 9.5mg/24h) for the treatment of moderately severe dementia, and behavioural symptoms of dementia, associated with Parkinson's disease. Rivastigmine patch formulation (4.6mg/24h, 9.5mg/24h and 13.3mg/24h) for the treatment of moderately severe dementia, and behavioural symptoms of dementia, associated with Alzheimer's disease. Conditions should be confirmed

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

113. Old age psychiatry: Clinical imaging in dementia with Lewy bodies

Old age psychiatry: Clinical imaging in dementia with Lewy bodies Clinical imaging in dementia with Lewy bodies | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clinical imaging in dementia with Lewy bodies Article Text Clinical review Old age psychiatry Clinical imaging in dementia with Lewy bodies Free Ajenthan Surendranathan , John Tiernan O’Brien Statistics from Altmetric.com Introduction Dementia with Lewy bodies (DLB

2018 Evidence-Based Mental Health

114. Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness and Guidelines

Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness and Guidelines Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness and Guidelines Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness (...) and Guidelines Published on: December 19, 2017 Project Number: RB1177-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of using environmental restraints for geriatric patients with dementia or psychosis in long-term care facilities? What are the evidence-based guidelines regarding the use of environmental restraints for patients with dementia or psychosis in long-term care facilities? Key Message No relevant

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

115. 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Full Text available with Trip Pro

18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 18F-florbetaben uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology (...) in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18F-florbetaben. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of 18F-florbetaben

2017 Cochrane

116. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Full Text available with Trip Pro

18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 18F-flutemetamol uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology (...) in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and the confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18F-flutemetamol. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of 18F-flutemetamol

2017 Cochrane

117. Validation of the 6-Item Cognitive Impairment Test and the 4AT test for combined delirium and dementia screening in older Emergency Department attendees Full Text available with Trip Pro

Validation of the 6-Item Cognitive Impairment Test and the 4AT test for combined delirium and dementia screening in older Emergency Department attendees screening for cognitive impairment in Emergency Department (ED) requires short, reliable tools.to validate the 4AT and 6-Item Cognitive Impairment Test (6-CIT) for ED dementia and delirium screening.diagnostic accuracy study.attendees aged ≥70 years in a tertiary care hospital's ED.trained researchers assessed participants using (...) the Standardised Mini Mental State Examination, Delirium Rating Scale-Revised 98 and Informant Questionnaire on Cognitive Decline in the Elderly, informing ultimate expert diagnosis using Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria for dementia and delirium (reference standards). Another researcher blindly screened each participant, within 3 h, using index tests 4AT and 6-CIT.of 419 participants (median age 77 years), 15.2% had delirium and 21.5% had dementia. For delirium detection

2017 EvidenceUpdates

118. Polycystic kidney disease is significantly associated with dementia risk (Abstract)

Polycystic kidney disease is significantly associated with dementia risk Data on the risk of neurodegenerative diseases, including Alzheimer disease (AD) and Parkinson disease (PD), in patients with polycystic kidney disease (PKD) are lacking.A total of 4,229 patients who were aged ≥20 years and had received a diagnosis of PKD were included in the PKD cohort. For each PKD case identified, 1 participant aged ≥20 years without a history of PKD, dementia, or PD was selected from the comparison (...) cohort. For each patient with PKD, the corresponding controls were selected 1:1 on the basis of the nearest propensity score calculated using logistic regression.The incidence density rates of dementia were 4.31 and 2.50 per 1,000 person-years in the PKD and control cohorts, respectively. A 2.04-fold higher risk of dementia was observed in patients with PKD than in controls (adjusted hazard ratio [aHR] 2.04; 95% confidence interval [CI] 1.46-2.85). Regarding the risk of different dementia subtypes

2017 EvidenceUpdates

119. CRACKCast E104 – Delirium and Dementia

CRACKCast E104 – Delirium and Dementia CRACKCast E104 – Delirium and Dementia - CanadiEM CRACKCast E104 – Delirium and Dementia In , by Adam Thomas August 28, 2017 This episode of CRACKCast covers Rosen’s Chapter 94, Delirium and Dementia. These are common presentations in the emergency department, and this episode will focus on screening, diagnosis, and management. Shownotes – Rosens in Perspective: “Delirium is characterized by a fluctuating neurobehavioral disturbance typically progressing (...) over a short period. It is a direct consequence of an acute systemic or central nervous system (CNS) stressor. Dementia, on the other hand, tends to follow a more gradual course, with evolution occurring over months to years. Although patients with dementia exhibit confusion, unlike delirium, manifestations of autonomic nervous system abnormalities are minimal or absent and a disturbance in level of consciousness usually is not a feature.” These big topics fall under the term neurobehavioural

2017 CandiEM

120. Tea, talk and technology: patient and public involvement to improve connected health ‘wearables’ research in dementia Full Text available with Trip Pro

Tea, talk and technology: patient and public involvement to improve connected health ‘wearables’ research in dementia There are a growing number of mobile phones, watches and electronic devices which can be worn on the body to track aspects of health and well-being, such as daily steps, sleep and exercise. Dementia researchers think that these devices could potentially be used as part of future research projects, for example to help spot changes in daily activity that may signal the early (...) symptoms of dementia. We asked a range of older people, including people living with dementia and their carers, to participate in interactive discussions about how future participants might find using these devices as part of research projects. We also invited volunteers to borrow a range of devices to test at home, giving them further insights. Discussions revealed that people were generally supportive of this type of research, provided they gave informed consent and that devices were discreet

2017 Research involvement and engagement